Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INFANT BACTERIAL THERAPEUTICS AB (PUBL)

(IBT B)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Infant Bacterial Therapeutics : announces that a new patent is granted in Mexico

09/13/2021 | 10:08am EDT

Infant Bacterial Therapeutics AB announces that the Mexican Patent Office has granted a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of Lactobacillus reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III. The ambition for IBP-9414 is to become the world's first approved probiotical drug with the goal to prevent life threatening diseases in premature infants including NEC and sepsis by promoting healthy stomach-and bowel development in premature infants.

The invention covers a novel way to activate the freeze-dried bacteria and corresponding patent applications are currently pending in additional future key markets including the US and Europe. This patent increases the existing protection of IBTs drug candidate IBP-9414 in addition to Orphan Drug Exclusivity and biological data protection already established in the US and EU.

The Mexican patent provides coverage until 2036. IBP-9414 is intended to be marketed in Mexico once marketing authorization has been obtained.

'It is a great pleasure that IBT has succeeded in expanding our intellectual property protection for IBP-9414' says Staffan Stromberg, Chief Executive Officer of IBT.

About Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB ('IBT') is a public company domiciled in Stockholm. The company's Class B shares are listed on Nasdaq Stockholm, Mid-cap (IBT B).

Infant Bacterial Therapeutics AB (publ) ('IBT') is a pharmaceutical company with a product in clinical phase III with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.

IBT is currently developing the drug candidate IBP-9414. The ambition for IBP-9414 is to become the world's first approved probiotical drug with the goal to prevent life threatening diseases in premature infants including NEC and sepsis by promoting healthy stomach-and bowel development in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.

Contact:

Staffan Stromberg

CEO

Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Phone: +46 70 477 04 73

E: info@ibtherapeutics.com

WEB: www.ibtherapeutics.com

Publication

This information is information that Infant Bacterial Therapeutics AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act.

The information was submitted for publication, through the agency of the contact persons set out above, at 12;30 CET on September 10, 2021.

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
BIOGAIA AB (PUBL) 0.21% 469.5 Delayed Quote.-12.57%
INFANT BACTERIAL THERAPEUTICS AB (PUBL) -1.80% 76.2 Delayed Quote.-31.96%
All news about INFANT BACTERIAL THERAPEUTICS AB (PUBL)
09/30INFANT BACTERIAL THERAPEUTICS : Next recruitment milestone reached in IBT's Phase III Stud..
AQ
09/30Infant Bacterial Therapeutics Announces Next Recruitment Milestone Reached in Ibt’S Pha..
CI
09/23INFANT BACTERIAL THERAPEUTICS : IBT - After safety review The Connection study is now agai..
AQ
09/22INFANT BACTERIAL THERAPEUTICS : After safety review The Connection study is now again open..
AQ
09/22Infant Bacterial Therapeutics AB Announces After Safety Review the Connection Study Is ..
CI
09/13INFANT BACTERIAL THERAPEUTICS : announces that a new patent is granted in Mexico
AQ
09/10INFANT BACTERIAL THERAPEUTICS : today announces that a new patent is granted in Mexico
AQ
09/10Infant Bacterial Therapeutics Announces the Mexican Patent Office Grants New Patent
CI
08/25INFANT BACTERIAL THERAPEUTICS : Recruitment of the smallest infants in the Connection stud..
AQ
08/25Infant Bacterial Therapeutics AB Announces Recruitment of the Smallest Infants in the C..
CI
More news
Financials
Sales 2020 - - -
Net income 2020 -72,0 M -8,37 M -8,37 M
Net cash 2020 423 M 49,2 M 49,2 M
P/E ratio 2020 -17,5x
Yield 2020 -
Capitalization 855 M 99,3 M 99,4 M
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 8
Free-Float 89,2%
Chart INFANT BACTERIAL THERAPEUTICS AB (PUBL)
Duration : Period :
Infant Bacterial Therapeutics AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INFANT BACTERIAL THERAPEUTICS AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
Staffan Str÷mberg Chief Executive Officer
Marie-Louise Alamaa Chief Financial Officer
Peter Michael Rothschild Chairman
Eamonn Connolly Chief Scientific Officer
Jonas Rastad Chief Medical Officer